Corporate Presentation
-
Upload
company-spotlight -
Category
Documents
-
view
707 -
download
0
Transcript of Corporate Presentation
Revolutionizing Vaccines
Dr. J. Joseph Kim President & CEO NYSE MKT: INO
Forward Looking Statement
Our commentary and responses to your questions may contain forward-looking statements, including comments concerning clinical trials and product development programs, evaluation of potential opportunities, the level of corporate expenditures, the assessment of Inovio’s technology by potential corporate partners, capital market conditions, timing of events, cash consumption and other subjects. Information concerning factors that could cause actual results to differ materially from those set forth in our Annual Report on Form 10-K for the year ended December 31, 2012, our Form 10-Q for the quarter ended September 30, 2013 and other regulatory filings from time to time.
2
3
2013: Dynamic Year • Best T cell responses in published clinical studies • Validating license deal with Roche in 2013
• $10 mm up-front, all development costs, $412.5 mm in milestones, plus royalties
2014: Transformative Year • Phase II efficacy data from lead drug mid-year • More cancer trials starting (cervical, head & neck, prostate,
breast, lung) • Additional pharma deals in the works
Inovio: Global Leader in Active Immune Therapy
4
Empowering Our Own Immune System to Defeat Disease
• Key player in effective immune therapy
• Kills tumors and infected cells • Are safe and tolerable
• Requires a directive to attack
T cells: Inovio Commands the Body’s SWAT Team
T cell Cytotoxic T lymphocyte
Target cell
5
T cells: Inovio Commands the Body’s SWAT Team
T cell Cytotoxic T lymphocyte
Target cell
Provided by Dr. Philip Greenberg Hutchinson Cancer Research Center
6
Recent PD-1 Clinical Data Validation: T cells All-Important in Immune Therapy
7
PD-1
PD-L1 Cancer cell
T cell
Passive Immune Therapy: Checkpoint Inhibitors
8
Passive
PD-1 Therapy
Checkpoint inhibitor
T cell
Passive Immune Therapy: Checkpoint Inhibitors
PD-1
PD-L1
9
Validation of Inovio’s aggressive T cell therapy
Active Immune Therapy: Inovio Therapeutic Vaccines
10
Best-in-class T cells with powerful killing effect
Active
T cells are the key to clinical outcome
Active Immune Therapy: Inovio Therapeutic Vaccines
11
12
Inovio: Leader in Active Cancer Immunotherapies
• Inovio cancer vaccines: Potential to increase efficacy
• Cervical/head & neck cancers • Breast cancer • Lung cancer • Pancreatic cancer • Melanoma • Prostate cancer
• Potential to improve safety and tolerability
• Major products in multi-billion market
• Unprecedented efficacy
• Melanoma • Lung cancer • Others
• Efficacy can be improved by
combining with active cancer vaccines
• Concerns about safety and tolerability signals
• Projected to be a $24 billion market
Powerful Combination of Active and Passive Immune Therapy
13
Inovio’s Technology
Plasmids
Electroporation device
• Synthetic DNA vaccines highly optimized for antigen expression
• SynCon® sequences designed to break tolerance or provide universal protection
• CELLECTRA® electroporation ideal delivery of DNA vaccines
• Best-in-class immune responses
• Favorable safety profile • Over 400 patents
Inovio’s Technology
14
#1 in Generating and Driving T Cell Responses in People
15
VGX-3100: Phase I Study Data
• Strong T-cell response in 14 of 18 (78%) vaccinated subjects at month 4
• 83% response rate in highest dose group
*Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med. 2012 Oct; 4:155ra13. dOI:10.1126/scitranslmed.3004414
VGX-3100 Demonstrated Best In Class T cell Responses
16
• 9 month durability of robust T cell response in 12/14 responders
• Safe & well tolerated
Source: Science Translational Medicine Oct. 2012 17
• 10/11 responders showed killing effect against target cells
Durable T cell Responses and T Cell Killing Effects
PENNVAX® HIV Vaccine: Highest CD8+ T cell Responses
Ref: Kalams et al JID 2013
18
A: 3X vaccination without EP B: 4X vaccination without EP C: 2x vaccination with EP (month 2) D: 3x vaccination with EP (month 4) E: Memory response (month 9)
A B C D E
Broad Medical and Market Opportunities
Product Name
INTERNALLY FUNDED
Indication Preclinical Phase I Phase II
Vgx-3100
Ino-5150
Ino-1400
EXTERNALLY FUNDED
pennvax®
Ino-3510
Ino-8000
ino-1800
malaria MaV-12
Phase III
Preventive
19
INO-3112
INO-3112
Preventive
Hepatitis C Therapeutic
Hepatitis B Therapeutic
influenza
Preventive
hiv
Preventive/Th
erapeutic
Breast/lung cancers
Therapeutic
Prostate cancer Therapeutic
Head & Neck Cancer Therapeutic
Cervical Cancer Therapeutic
Cervical dysplasia
Therapeutic
Inovio’s Lead Program
VGX-3100: • Capitalizes on Inovio’s ability to generate T cells • Immunotherapy for pre-cancers and cancers caused by
human papillomavirus (HPV) • Phase II on-going: high grade cervical pre-cancers (CIN
2/3 dysplasia) • Projected efficacy data: mid-2014
20
Inovio’s Lead Program
21
22
Inovio’s Lead Program
Broad Medical and Market Opportunities
HPV product franchise planning • CIN 2/3 phase III • Other HPV-related indications (cervical cancer and head/neck
cancer): initiate phase II studies • Orphan designation potential
23
INO-1400: Potential Universal Cancer Therapy
Yan J et al., Cancer Immunol Res. (2013) 24
25
Broad Base of Support for Inovio
Almost $60M in non-dilutive funding since 2009
Power of our People
• Management • Board of Directors • Scientific Advisory Board
26
Louis Pasteur
Peter Kies CFO • Ernst & Young • Experience with growth companies
Mark L. Bagarazzi, MD CMO • Clinical research experience incl. Merck • Led clinical/regulatory for shingles and rotavirus vaccines; DNA vaccine expert
27
J.Joseph Kim, PhD President & CEO
• Decades of biotechnology/pharma management
• Merck: hepatitis A and B vaccines manufacturing; HIV vaccine (Ad5) R&D
Niranjan Y. Sardesai, PhD COO
• Extensive biotech management and product development experience
• Led development of diagnostics for mesothelioma, bladder cancer, and ovarian
cancer for Fujirebio Diagnostics
Management
Louis Pasteur J.Joseph Kim, PhD • President & CEO, Inovio
Adel Mahmoud, PhD • Professor, Princeton University • Former President, Merck Vaccines • Responsible for Gardasil®, Zostavax®, Proquad® and Rotateq®
Morton Collins, PhD • General Partner, Battelle Ventures and Innovations Valley Partners
28
Simon X. Benito • Former Senior Vice President,
Merck Vaccine Division
Angel Cabrera, PhD • President, George Mason University
• Former President, Thunderbird School of Global Management
Avtar Dhillon, MD Chairman, BOD
• Former President & CEO, Inovio Biomedical
Board of Directors
Louis Pasteur Stanley A. Plotkin, MD • Developed rubella and rabies vaccines • Oversaw Sanofi flu vaccine • Emeritus Professor, Wistar Institute & University of Pennsylvania
Philip Greenberg, MD • Expert in T-cell immunology • Head, Immunology Program, Fred Hutchinson Cancer Research Center
29
Thomas S. Edgington, MD • Founded multiple biotech companies;
extensively published • Emeritus Professor, Scripps
Research Institute
Anthony W. Ford-Hutchinson, PhD • Former SVP, Vaccines R&D, Merck
• Oversaw development: Singulair®, Januvia®, Gardasil®, Zostavax®, Proquad® and Rotateq®
David B. Weiner, PhD Chairman
•“Father of DNA vaccines” • Dept. of Pathology & Laboratory Medicine,
University of Pennsylvania
Scientific Advisory Board
30
2/1/13 3/1/13 4/1/13 5/1/13 6/1/13 7/1/13 8/1/13 9/1/13 10/1/13 11/1/13 12/1/13 1/1/14 2/1/14
Stock Price
Financial Information
Cash, cash equivalents & short-term investments1 $ 46.3 M
Debt1 0 M
Cash runway 1Q 2016
Issued & outstanding shares2 211.4 M
Recent price3 $2.49
Market cap3 $526.4 M
NYSE MKT: INO
1Sep. 30, 2013 3 Feb 3, 2014 31
Additional cash4 $ 11.1 M
2Jan 31, 2014 4 Nov 12, 2013
Upcoming Value Drivers
32
INTERNALLY FUNDED EXTERNALLY FUNDED
Ino-5150 1H 2014 Initiate phase I/IIa Prostate cancer
Vgx-3100
Mid-2014 Phase II study data Cervical dysplasia
INO-3112
1H 2014 Initiate phase I/IIa
Head & Neck Cancer
33
Upcoming Value Drivers
INO-3112
1H 2014 Initiate phase I/IIa
Cervical Cancer
Ino-1400
2014 Initiate phase I/IIa
Breast/lung Cancer
INTERNALLY FUNDED EXTERNALLY FUNDED
PennVAX2014 Initiate PENNVAX -GP phase I study HIV
Ino-8000
2015 Report phase I data Hepatitis C
MAV-12
2014 Initiate phase I/IIa
Malaria
34
Upcoming Value Drivers
Ino-1800
2014 Prepare phase I/IIa Hepatitis B
Investor Highlights • Break-through active immune therapy with the
power to save lives and maximize shareholder value
• Targeting broad range of diseases and billion dollar markets • Best-in-class T cells to prevent, treat & cure cancers and infectious diseases
• Phase II efficacy data coming
• Validating partnership with Roche with more deals in the works
The Opportunity
35
Bernie Hertel Senior Director, Communications & Investor Relations 858-410-3101 [email protected]
Investor Contact
Investor Contact
36